Canadian Ticagrelor Survey

Study identifier:D5130L00009

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Effectiveness of risk minimisation interventions for ticagrelor in Canada

Medical condition

Acute Coronary Syndrome

Phase

N/A

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

244

Study type

Observational

Age

18 Years - 85 Years

Date

Study Start Date: 01 Nov 2012

Primary Completion Date: 01 Dec 2014

Study Completion Date: 01 Dec 2014

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Dec 2015 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Montreal, Quebec, Canada

Arms	Assigned Interventions
Prescribers	-

Documents available

CSR Synopsis
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

Investigators

Principal Investigator

Yola Moride

University of Montreal